ImpriMed Series A2 (2026)
ImpriMed raised $10 million in a Series A2 bridge round, announced on 2026-09-21. The round was led by LB Investment.
- Company
- ImpriMed
- Round type
- Series A2
- Date
- 2026-09-21
- Amount
- $10M
- Industry
- precision medicine, oncology, healthcare AI
- Location
- Seoul, South Korea
Summary
ImpriMed raised $10 million in Series A2 bridge funding announced on 2026-09-21, led by LB Investment. New investors include NAVER D2SF, Samsung Securities and Alois Ventures; existing investors BonAngels and Han River Partners also participated.
Investors
Lead
- LB Investment lead
Participating
- NAVER D2SF participant
- Samsung Securities participant
- Alois Ventures participant
- BonAngels participant
- Han River Partners participant
Sources
Last verified:
- https://www.finsmes.com/2026/09/imprimed-raises-10m-in-series-a2-bridge-funding.html
Type: reputable publication. Accessed 2026-10-07.
FinSMEs article dated 2026-09-21. Reports a $10 million Series A2 bridge led by LB Investment with NAVER D2SF, Samsung Securities, Alois Ventures, BonAngels and Han River Partners, and a Seoul location. - https://www.citybiz.co/article/905872/naver-d2sf-invests-in-imprimeds-10-million-precision-medicine-round/
Type: reputable publication. Accessed 2026-10-07.
Citybiz article. Confirms NAVER D2SF joined the $10 million Series A2 bridge led by LB Investment with Samsung Securities, Alois Ventures, BonAngels and Han River Partners.